OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

作者：S.S. Ramalingam, T-E. Ciuleanu, R. Bernabe, Makoto Nishio, H. Mizutani, J.-S. Lee, C. Audigier-Valette, Randeep Sangha, László Urbán, J.A. Burgers, A. Pluzanski, Ki Hyeong Lee, B. Zurawski, M. Schenker, Solange Peters, Luis Paz‐Ares, H. Borghaei, K.J. O’Byrne, J.R. Brahmer, R.G. Gupta, Judith Bushong, Li Li, Yong Yuan, Steven I. Blum, Martin Reck · 发表于：Journal of Thoracic Oncology · 年份：2023 · DOI：10.1016/j.jtho.2023.09.076 · 被引用次数：12 · 研究领域：Cancer Immunotherapy and Biomarkers、Colorectal Cancer Treatments and Studies、Lung Cancer Treatments and Mutations